These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 29486762

  • 1. Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context.
    Schmid MK, Reich O, Blozik E, Faes L, Bodmer NS, Locher S, Thiel MA, Rapold R, Kuhn M, Bachmann LM.
    BMC Ophthalmol; 2018 Feb 27; 18(1):64. PubMed ID: 29486762
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life.
    Schmid MK, Reich O, Faes L, Boehni SC, Bittner M, Howell JP, Thiel MA, Signorell A, Bachmann LM.
    PLoS One; 2015 Feb 27; 10(8):e0135050. PubMed ID: 26241852
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland.
    Reich O, Schmid MK, Rapold R, Bachmann LM, Blozik E.
    BMC Ophthalmol; 2017 Dec 04; 17(1):234. PubMed ID: 29202760
    [Abstract] [Full Text] [Related]

  • 5. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA, American Society of Retina Specialists Anti-VEGF for Diabetic Macular Edema Comparative Effectiveness Panel.
    JAMA Ophthalmol; 2016 Jan 04; 134(1):95-9. PubMed ID: 26512939
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters.
    Elshout M, van der Reis MI, Webers CA, Schouten JS.
    Graefes Arch Clin Exp Ophthalmol; 2014 Dec 04; 252(12):1911-20. PubMed ID: 24777708
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M, Fassnacht-Riederle H, Becker MD, Graf N, Michels S.
    Ophthalmic Res; 2015 Dec 04; 54(3):150-6. PubMed ID: 26413794
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of Eylea® with Lucentis® as first-line therapy in patients with treatment-naïve neovascular age-related macular degeneration in real-life clinical practice: retrospective case-series analysis.
    Böhni SC, Bittner M, Howell JP, Bachmann LM, Faes L, Schmid MK.
    BMC Ophthalmol; 2015 Aug 20; 15():109. PubMed ID: 26289356
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
    Pinheiro-Costa J, Costa JM, Beato JN, Freitas-da-Costa P, Brandão E, Falcão MS, Falcão-Reis F, Carneiro ÂM.
    Ophthalmologica; 2015 Aug 20; 233(3-4):155-61. PubMed ID: 25896317
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Aflibercept versus ranibizumab for treating persistent diabetic macular oedema.
    Vandekerckhove KR.
    Int Ophthalmol; 2015 Aug 20; 35(4):603-9. PubMed ID: 25989873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.